CRNX · Categories · Form 4

CRNX - SEC Form 4 insider transactions

Crinetics Pharmaceuticals Inc. (CRNX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for CRNX

• 8d
  President & CEO Struthers Richard Scott gifted 968,800 shares and received a gift of 968,800 shares (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 61d
  SEC Form 4 filed by Knight Jeff E.

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 84d
  SEC Form 4 filed by Crinetics Pharmaceuticals Inc.

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 84d
  SEC Form 4 filed by Knight Jeff E.

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 84d
  SEC Form 4 filed by Struthers Richard Scott

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 89d
  Director Vivaldi Coelho Rogerio sold $180,761 worth of shares (5,000 units at $36.15), decreasing direct ownership by 23% to 16,300 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 98d
  Director Okey Stephanie sold $119,010 worth of shares (3,000 units at $39.67), decreasing direct ownership by 18% to 13,300 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 98d
  Chief Financial Officer Schilke Tobin sold $266,305 worth of shares (6,713 units at $39.67), decreasing direct ownership by 8% to 78,121 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 105d
  President & CEO Struthers Richard Scott was granted 62,000 shares, increasing direct ownership by 17% to 426,759 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 105d
  Chief Financial Officer Schilke Tobin was granted 32,000 shares, increasing direct ownership by 61% to 84,834 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 105d
  Chief Operating Officer Knight Jeff E. was granted 34,000 shares, increasing direct ownership by 39% to 121,929 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 105d
  Chief Scientific Officer Betz Stephen F. was granted 30,000 shares, increasing direct ownership by 25% to 147,713 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 105d
  Chief Commercial Officer Kalofonos Isabel was granted 34,000 shares, increasing direct ownership by 4,077% to 34,834 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 154d
  Chief Commercial Officer Kalofonos Isabel exercised 2,500 shares at a strike of $40.59 and sold $137,500 worth of shares (2,500 units at $55.00) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 163d
  Chief Scientific Officer Betz Stephen F. exercised 18,000 shares at a strike of $1.91, increasing direct ownership by 18% to 117,713 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 174d
  President & CEO Struthers Richard Scott exercised 44,742 shares at a strike of $13.09, increasing direct ownership by 14% to 364,759 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 189d
  Chief Med and Dev Officer Pizzuti Dana exercised 5,000 shares at a strike of $16.89 and sold $225,100 worth of shares (5,000 units at $45.02) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 217d
  Chief Med and Dev Officer Pizzuti Dana exercised 5,000 shares at a strike of $16.89 and sold $213,312 worth of shares (5,000 units at $42.66) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 250d
  Chief Med and Dev Officer Pizzuti Dana exercised 5,000 shares at a strike of $16.89 and sold $209,050 worth of shares (5,000 units at $41.81) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 253d
  President & CEO Struthers Richard Scott sold $180,000 worth of shares (4,000 units at $45.00) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 253d
  Director Fust Matthew K exercised 10,000 shares at a strike of $1.91 and sold $716,000 worth of shares (16,000 units at $44.75), decreasing direct ownership by 21% to 22,836 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 279d
  Chief Med and Dev Officer Pizzuti Dana exercised 5,000 shares at a strike of $16.89 and sold $160,500 worth of shares (5,000 units at $32.10) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 288d
  Chief Med and Dev Officer Pizzuti Dana exercised 30,000 shares at a strike of $16.89 and sold $912,900 worth of shares (30,000 units at $30.43) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 293d
  Chief Med and Dev Officer Pizzuti Dana sold $189,437 worth of shares (6,492 units at $29.18), decreasing direct ownership by 9% to 66,270 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 359d
  Chief Scientific Officer Betz Stephen F. exercised 88,170 shares at a strike of $3.30 and sold $3,141,877 worth of shares (97,483 units at $32.23), decreasing direct ownership by 9% to 99,713 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 362d
  Director Deardorf Caren was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 362d
  Director Okey Stephanie was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 362d
  Director Vivaldi Coelho Rogerio was granted 6,900 shares, increasing direct ownership by 48% to 21,300 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 362d
  Director Bedrosian Camille L was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 362d
  Director Nichols Weston was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 362d
  Director Wierenga Wendall was granted 6,900 shares, increasing direct ownership by 6% to 116,146 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 362d
  Director Fust Matthew K was granted 6,900 shares, increasing direct ownership by 31% to 28,836 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 390d
  President & CEO Struthers Richard Scott gifted 90,400 shares and received a gift of 90,400 shares, decreasing direct ownership by 22% to 320,017 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 432d
  President & CEO Struthers Richard Scott exercised 81,270 shares at a strike of $1.91, increasing direct ownership by 25% to 410,417 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 446d
  Chief Med and Dev Officer Pizzuti Dana sold $86,021 worth of shares (2,515 units at $34.20), decreasing direct ownership by 3% to 72,233 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 446d
  Chief Operating Officer Knight Jeff E. sold $244,964 worth of shares (7,162 units at $34.20), decreasing direct ownership by 8% to 87,491 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 446d
  Chief Scientific Officer Betz Stephen F. sold $197,353 worth of shares (5,770 units at $34.20), decreasing direct ownership by 5% to 108,588 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 446d
  President & CEO Struthers Richard Scott sold $593,017 worth of shares (17,338 units at $34.20), decreasing direct ownership by 5% to 329,147 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 456d
  Chief Financial Officer Schilke Tobin was granted 52,000 shares (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 471d
  President & CEO Struthers Richard Scott was granted 89,000 shares, increasing direct ownership by 35% to 346,485 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 471d
  Chief Operating Officer Knight Jeff E. was granted 43,000 shares, increasing direct ownership by 83% to 94,653 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 471d
  Chief Med and Dev Officer Pizzuti Dana was granted 43,000 shares, increasing direct ownership by 135% to 74,748 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 471d
  Chief Scientific Officer Betz Stephen F. was granted 43,000 shares, increasing direct ownership by 60% to 114,358 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 490d
  Chief Med and Dev Officer Pizzuti Dana exercised 5,000 shares at a strike of $16.89 and sold $195,350 worth of shares (5,000 units at $39.07) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 513d
  SEC Form 4 filed by Chief Commercial Officer Kalofonos Isabel

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 519d
  Chief Med and Dev Officer Pizzuti Dana exercised 17,500 shares at a strike of $17.28 and sold $781,350 worth of shares (15,000 units at $52.09), increasing direct ownership by 9% to 31,748 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 539d
  Chief Scientific Officer Betz Stephen F. exercised 2,331 shares at a strike of $1.91, increasing direct ownership by 3% to 71,358 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 553d
  President & CEO Struthers Richard Scott sold $575,700 worth of shares (10,000 units at $57.57) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 561d
  Chief Operating Officer Knight Jeff E. sold $28,317 worth of shares (501 units at $56.52), decreasing direct ownership by 0.96% to 51,653 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 612d
  Chief Med and Dev Officer Pizzuti Dana exercised 14,375 shares at a strike of $16.89 and sold $785,306 worth of shares (14,375 units at $54.63) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 618d
  CFO Wilson Marc exercised 25,000 shares at a strike of $15.29 and sold $1,277,750 worth of shares (25,000 units at $51.11) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 636d
  Chief Scientific Officer Betz Stephen F. sold $53,302 worth of shares (1,035 units at $51.50), decreasing direct ownership by 1% to 68,576 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 651d
  Chief Scientific Officer Betz Stephen F. sold $159,570 worth of shares (3,000 units at $53.19), decreasing direct ownership by 4% to 69,611 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 665d
  Chief Scientific Officer Betz Stephen F. sold $143,040 worth of shares (3,000 units at $47.68), decreasing direct ownership by 4% to 72,611 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 684d
  Chief Scientific Officer Betz Stephen F. sold $160,290 worth of shares (3,000 units at $53.43), decreasing direct ownership by 4% to 75,611 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 684d
  CFO Wilson Marc exercised 19,056 shares at a strike of $9.28 and sold $1,026,737 worth of shares (19,056 units at $53.88) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 693d
  Chief Operating Officer Knight Jeff E. exercised 26,073 shares at a strike of $22.59 and sold $1,485,000 worth of shares (27,000 units at $55.00), decreasing direct ownership by 2% to 51,653 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 693d
  CFO Wilson Marc exercised 25,000 shares at a strike of $20.02 and sold $1,375,000 worth of shares (25,000 units at $55.00) (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 698d
  Chief Scientific Officer Betz Stephen F. sold $145,650 worth of shares (3,000 units at $48.55), decreasing direct ownership by 4% to 78,611 units (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
• 701d
  Chief Commercial Officer Hassard James sold $661,200 worth of shares (15,000 units at $44.08) and exercised 15,000 shares at a strike of $19.73 (SEC Form 4)

  4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

Other CRNX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends